

図2 簡便なHTLV-I抗原の定量(ELISA/FCM)

A: Gag p24抗原のサンドイッチELISA(直接法)。直接ELISAなので、反応は1ステップで終了し、発色も含めて1時間弱で終了する。細胞培養上清でも、細胞可溶化溶液でも測定が可能である。
B: Tax抗原のフローサイトメトリー(FCM)。HTLV-I感染者の新鮮PBMCを15~24時間培養し、生細胞を30分anti-CD4で染色後、PFA固定/サポニン膜透過液で処理してanti-Tax Lt-4で30分の最終染色を行う。その後、常法に従ってFCMを行い、解析する。

に結合し、引き続きエンベロープgp21を使って細胞に侵入すると考えられている¹⁰⁾。しかし、他のウイルスと比較してHTLV-I粒子の大部分が感染粒子として不完全でありその感染性が非常に低い。また易熱性で冷蔵してもすぐに失活する¹¹⁾。したがって、*in vitro*でも生体内でも感染成立にはウイルス粒子単独でなく、HTLV-I産生細胞と標的細胞が直接コンタクトすることが必要と考えられている。このようにHTLV-Iがcell to cell感染で伝染する環境では、エイズやインフルエンザウイルスの場合とは異なり、中和抗体がウイルスに直接ウイルス粒子に干渉することはない。このことは、種々のHTLV-I野生株においてエピトープの変異がほとんどないこと¹²⁾と一致し、HTLV-Iの標準株を標的として感染防御ワクチンを開発する妥当性を強く後押しする。

HTLV-IがヒトT細胞のみならず、調べたすべての脊椎動物細胞株やヒトのリンパ球以外の種々のヒトの血液細胞に感染するため、受容体は長い間不明のままであったが、エンベロープgp46の機能的領域が徐々に解明され、これまで受容体機能を持つ3分子が報告されている。すなわち、heparan sulfate proteoglycans(HSPG)、neuropilin1(NRP-1)およびglucose transporter type 1(GLUT1)であるが、これら3分子が複合してHTLV-I感染に関与することが推測されてい

る¹³⁾¹⁴⁾。HSPGへの結合はgp46のC末領域(CTD)が、NRP-1とGLUT1への結合にはアミノ酸88-120の受容体結合領域(RBD)が関与するとされている¹⁴⁾。しかし、ヒト生体内の感染にこのような受容体候補が実際にどのように働いているのか、特にCD4陽性T細胞への感染においてはどのようなのは今後の研究課題である。また、HTLV-I感染予防において受容体を標的とする戦略も考えられるが、今のところ実現性に乏しい。

感染中和エピトープ

ヒト血清抗体や免疫動物のHTLV-I中和抗体の認識エピトープを調べると、興味あることに、上記のウイルス受容体との結合関連領域RBDに含まれない領域[特に中央部のプロリンリッチ領域(PRD)内のアミノ酸190番付近や、gp46の高次構造]にも中和エピトープが存在する⁹⁾¹⁵⁾¹⁶⁾。gp46は感染においてその高次構造の動的変化が重要なことが示唆される。したがって、HTLV-Iの初感染あるいは体内での再感染を防ぐ機能を持つ能動ワクチンは、このようにHTLV-Iエンベロープの中和エピトープを認識する抗体を効率よく誘導する機能が求められる。HTLV-Iキャリア由来のB細胞をEBV感染でトランスフォームして得られたヒト型HTLV-I中和単クローン抗体の研究がいくつか報告され、ヒトにおいてもPRD領域




図3 HTLV-I感染の中和能：合胞体形成の阻止

が中和エピトープの集中する領域として認識されることが証明されている⁹⁾¹⁷⁾。これらの事実から、能動ワクチンの標的候補としてgp46 PRD領域のエピトープがワクチン候補として注目される。

感染防御ワクチン開発の研究基盤の確立

われわれが2011年から再開したHTLV-Iのワクチン開発へ向けた基礎研究では以下に示すように、まずHTLV-I感染防御能を評価する実験系の確立から行った¹⁸⁾¹⁹⁾。

(1)HTLV-I感染を定量するアッセイ系の確立：これまで作製した単クローン抗体ライブラリーを駆使し、HTLV-I抗原のp24やgp46を定量するELISA法、Tax抗原発現細胞のフローサイトメトリー法を確立した(図2)。

(2)*In vitro*感染系の確立：合胞体形成を指標とする感染実験において、HTLV-IはT細胞以外のヒト細胞株や異種動物の細胞株にも感染するが、あえて標的をヒトT細胞株にこだわり、種々のHTLV-I産生細胞株と種々のヒトT細胞株の組み

合わせで最も判定しやすい合胞体を形成する組み合わせをスクリーニングした。ILT-M1とJurkat細胞が選択された。図3に示すようにこの系では、細胞と細胞を1:1で混合し一晩培養するだけで巨大な合胞体が形成される。5 µg/ml以上のLAT-27を添加すると合胞体形成が完全に阻止される。他のアッセイ系ではできた合胞体数を測定して%中和効率を算定しているが、この系では合胞体形成の完全阻止を中和のエンドポイントとしてヒト血清の中和抗体価の定量に用いている。100%防御でなければ、感染が成立するからである。また、ILT-M1細胞は混合培養により効率よく活性化PBMCを不死化する能力を持ち合わせるため、2~3週間後にTax陽性細胞のフローサイトメトリーを行えば、正常T細胞への感染が確認できるので、この系も中和抗体の機能確認に利用できる。抗体の不死化阻止効率と合胞体阻止効率はほぼ相関した(未発表)。

(3)動物感染実験系の確立：これまでHTLV-I感染感受性動物としてウサギが使用されていたが、近交系ラットも感受性が低いながらもHTLV-Iに感染することに注目した。このラットの系では、




図4 LAT-27と新鮮PBMCによる自家HTLV-I感染細胞株の駆逐
HTLV-I感染細胞株に同じドナー由来(自家)の新鮮末梢血単核球(PBMC)とLAT-27を添加して培養すると、Tax陽性細胞数が激減し、同じ操作を2~3回繰り返すことによりHTLV-I感染細胞株が消滅する。この効果はLAT-27 F(ab')₂では観察されない。同じような抑制効果はHAM患者由来のIgG抗体でも観察された。右下の顕微鏡者写真のようにHTLV-I感染細胞株は消失する。

経口を含めた種々の感染ルートからのHTLV-I感染を中和抗体が防御できるかを検討している¹⁹⁾。また、HTLV-I陰性成人のPBMCを免疫不全マウスに移植したヒト化マウスにおける中和抗体の感染防御実験系についてもほぼ確立した。

(4)ワクチン候補は主に合成ペプチドを基本としてデザインしており、ラットやマウスに免疫し、種々の候補の中和抗体誘導能を比較している。これまでのところ、gp46抗原のPRD内のアミノ酸配列を持つペプチドが中和抗体誘導能に優れていた(未発表)。

HTLV-I感染自家細胞株の駆逐

上記の基盤を使って、実際に中和活性を持つLAT-27や他の抗体のウイルス産生抑制およびTax陽性細胞の駆逐能を比較検討した。そして、中和単クローン抗体LAT-27がHTLV-I感染者PBMC培養においてTax陽性細胞の出現頻度を下げ、さらに培養を続けるとT細胞の不死化をも顕著に抑制することを見出した¹⁸⁾。このような効果は非中和anti-gp46抗体では観察できなかった。そのメカニズムをさらに探るため、健常人のT細胞をHTLV-Iで不死化した細胞株を樹立し、自家新鮮PBMCとLAT-27存在下で混合培養したところ、HTLV-I感染細胞株が駆逐された。LAT-27のFc部

を消化したF(ab')₂フラグメントは感染中和活性を持つものの駆逐効果は観察できなかった²⁰⁾。つまり、駆逐にはIgG-Fc部が関与しているのである。同じような駆逐効果はHTLV-Iに対して高力価の中和能を示すHAM患者血清由来のIgGでも観察された(図4)。駆逐のメカニズムの一つにはナチュラルキラー細胞(NK)をエフェクターとするADCCの関与が示唆された。ヒトHTLV-I抗体を介するADCCによるHTLV-I感染細胞株の障害性については過去に多くの研究発表がなされているが²¹⁾²²⁾、このような*in vitro*の実験結果からも、HTLV-I感染防御を目的とするワクチン標的とすべき第一の候補はHTLV-Iエンベロップgp46であること、抗体を使った受動免疫ワクチン候補としてヒト化したLAT-27があげられることが導き出される。

結 論

いまだHTLV-I能動ワクチンの開発には成功していないが、これまで私どもが開発した*in vitro*と*in vivo*のワクチン評価基盤を用いて安全性に優れた合成ペプチドワクチンを中心にスクリーニングを進めている。

これまで抗体の受動免疫によるHTLV-I母乳初期感染の防御についてはウサギでの感染実験で




図5 HTLV-I Env gp46抗体を介するHTLV-I感染制御ワクチン作製への礎

明らかにされ²³⁾, ヒトanti-HTLV-I抗体がサルにおいて受動免疫効果を持つことも報告されているが²⁴⁾, HTLV-Iの制御において抗体がどれだけ重要なのかを実証する研究はなかった。本稿では, LAT-27の中和効果および新鮮自家PBMCとの共同によるADCC様のウイルス感染細胞駆除効果を紹介した。同じ効果はHAM患者由来ポリクローナルIgGでも観察されたことから, 1つの抗体がこのような2つの機能を持たなくとも, 中和機能を持つ抗体とADCC機能を持つ別の抗体がいっしょに十分にあれば*in vivo*におけるHTLV-I感染防御と感染細胞の監視は十分にできると推察できる(図5)。

現在, LAT-27をヒト型化する作業を進行している。近い将来, ヒト化LAT-27は中和抗体活性の低いHTLV-Iキャリア。特に妊婦の方々を対象とした受動免疫抗体薬として活用できることを期待しており, 現在, ラットでの垂直感染阻止実験を行っている。LAT-27のようなHTLV-I感染細胞上のウイルス抗原を認識する抗体医薬は, 現在のanti-CCR4²⁵⁾やanti-CD25抗体²⁰⁾と併用することによりさらに高いウイルス制御活性を発揮すると期待される。

雑談

ATLウイルスは, 米国で1980年に米国Gallo博士らが報告した“みなしごウイルス”ヒトT細胞白血病ウイルス(human T-cell leukemia virus type-I, HTLV-I)と同一であることがわかり, 2つ

の名前はHTLV-Iに統一された。その後, HTLV-Iがエイズの原因ウイルス(HTLV-III)の仲間であるとされ, HTLV-Iは“human T lymphocyte-tropic virus type-I”と名称が勝手に変更された。また最近の論文ではHTLV-1と記載されることが多く見られるが正しくはHTLV-Iであり, それはhuman T-cell leukemia virus type-Iの略である。(ウラマタロウ)

文献

- 1) Satake M, Yamaguchi K, Tadokoro K. Current prevalence of HTLV-1 in Japan as determined by screening of blood donors. *J Med Virol* 2012 84 327
- 2) Hinuma Y, Nagata K, Hanaoka M, et al. Adult T cell leukemia antigen in an ATL cell line and detection of antibodies to the antigen in human sera. *Proc Natl Acad Sci U S A* 1981 78 6476.
- 3) Yamamoto N, Matsumoto T, Koyanagi Y, et al. Unique cell lines harbouring both Epstein-Barr virus and adult T-cell leukaemia virus, established from leukaemia patients. *Nature* 1982 299 367
- 4) Tanaka Y, Inoi T, Tozawa H, et al. A glycoprotein antigen detected with new monoclonal antibodies on the surface of human lymphocytes infected with human T-cell leukemia virus type-I (HTLV-I). *Int J Cancer* 1985 36 549.
- 5) Tanaka Y, Lee B, Inoi T, et al. Antigens related to three core proteins of HTLV-I (p24, p19 and p15) and their intracellular localizations, as defined by monoclonal antibodies. *Int J Cancer* 1986 37 35.
- 6) Tanaka Y, Zeng L, Shiraki H, et al. Identification of a neutralization epitope on the envelope gp46 antigen of human T cell leukemia virus type I and induction of neutralizing antibody by peptide immunization. *J Immunol* 1991 147 354.
- 7) Hakoda E, Machida H, Tanaka Y, et al. Vaccination of rabbits with recombinant vaccinia virus carrying the envelope gene of human T-cell lymphotropic virus type I. *Int J Cancer* 1995 60 567
- 8) Baba E, Nakamura M, Ohkuma K, et al. A peptide-based human T cell leukemia virus type I vaccine containing T and B cell epitopes that induces high

- titers of neutralizing antibodies. *J Immunol* 1995 154 399.
- 9) Kuroki M, Nakamura M, Itoyama Y et al. Identification of new epitopes recognized by human monoclonal antibodies with neutralizing and antibody-dependent cellular cytotoxicity activities specific for human T cell leukemia virus type 1. *J Immunol* 1992 149 940.
 - 10) Lairmore MD, Haines R, Anupam R. Mechanisms of human T-lymphotropic virus type 1 transmission and disease. *Curr Opin Virol* 2012 2 474.
 - 11) Shinagawa M, Jinno-Oue A, Shimizu N, et al. Human T-cell leukemia viruses are highly unstable over a wide range of temperatures. *J Gen Virol* 2012 93 608.
 - 12) Suzuki Y, Gojobori T. The origin and evolution of human T-cell lymphotropic virus types I and II. *Virus Genes* 1998 16 69.
 - 13) Hoshino H. Cellular Factors Involved in HTLV-1 Entry and Pathogenicity. *Front Microbiol* 2012 3 222.
 - 14) Jones KS, Lambert S, Bouttier M, et al. Molecular aspects of HTLV-1 entry functional domains of the HTLV-1 surface subunit (SU) and their relationships to the entry receptors. *Viruses* 2011 3 794.
 - 15) Blanchard S, Astier-Gin T, Tallet B, et al. Amino acid changes at positions 173 and 187 in the human T-cell leukemia virus type 1 surface glycoprotein induce specific neutralizing antibodies. *J Virol* 1999 73 9369.
 - 16) Astier-Gin T, Portail JP, Londos-Gagliardi D, et al. Neutralizing activity and antibody reactivity toward immunogenic regions of the human T cell leukemia virus type I surface glycoprotein in sera of infected patients with different clinical states. *J Infect Dis* 1997 175 716.
 - 17) Hadlock KG, Rowe J, Perkins S, et al. Neutralizing human monoclonal antibodies to conformational epitopes of human T-cell lymphotropic virus type 1 and 2 gp46. *J Virol* 1997 71 5828.
 - 18) 田中勇悦, 長谷川温彦, 神奈木真理, ほか HTLV-I感染T細胞の不死化とウイルス産生を制御する宿主免疫環境 [会] 第60回日本ウイルス学会学術集会抄録 2012年11月13~15日 大阪. p.356. 抄録番号 P1-092.
 - 19) 村上悠一, 安藤聡美, 長谷川温彦 ほか ラットモデルにおけるHTLV-I中和単クローン抗体のHTLV-I感染防御 [会] 第60回日本ウイルス学会学術集会抄録 2012年11月13~15日, 大阪. p.358. 抄録番号 P1-095.
 - 20) Chen J, Zhang M, Ju W, Waldmann TA. Effective treatment of a murine model of adult T-cell leukemia using depsi-peptide and its combination with unmodified daclizumab directed toward CD25. *Blood* 2009 113 1287
 - 21) Miyakoshi H, Koide H, Aoki T. In vitro antibody-dependent cellular cytotoxicity against human T cell leukemia/lymphoma virus (HTLV)-producing cells. *Int J Cancer* 1984 33 287
 - 22) Kunitomi T, Takigawa H, Sugita M, et al. Antibody-dependent cellular cytotoxicity and natural killer activity against HTLV-1 infected cells. *Acta Paediatr Jpn* 1990 32 16.
 - 23) Sawada T, Iwahara Y, Ishii K, et al. Immunoglobulin prophylaxis against milkborne transmission of human T cell leukemia virus type I in rabbits. *J Infect Dis* 1991 164 1193.
 - 24) Murata N, Hakoda E, Machida H, et al. Prevention of human T cell lymphotropic virus type I infection in Japanese macaques by passive immunization. *Leukemia* 1996 10 1971.
 - 25) Tobinai K. Clinical trials for human T-cell lymphotropic virus type I-associated peripheral T-cell lymphoma in Japan. *Semin Hematol* 2010 47 Suppl 1 S5.

* * *

HTLV-1

M Saito, University of the Ryukyus, Okinawa, Japan

© 2013 Elsevier Inc. All rights reserved.

This article is a revision of the previous edition article by MJS Dyer, volume 1, p 979, © 2001, Elsevier Inc.

Glossary

Cytotoxic T cell A cytotoxic T cell belongs to a subgroup of T lymphocytes with CD8 receptor that are antigen-specific and capable of inducing the death of virus-infected somatic or tumor cells.

Gliosis Gliosis is the process of scarring in the central nervous system, caused by a proliferation of astrocytes.

Oligoclonal band Oligoclonal bands are bands of immunoglobulins that are seen when a blood serum (or plasma) or cerebrospinal fluid (CSF) is analyzed by protein electrophoresis. The presence of oligoclonal bands

in CSF but not in blood serum (or plasma) means the production of immunoglobulins in central nervous system, that is, inflammation in the central nervous system.

Provirus A provirus is the form of the virus which is capable of being integrated into the chromosome of the host cell.

Spastic paraparesis Mild or moderate loss of motor function accompanied by spasticity in the extremities mainly caused by central nervous system (brain and spinal cord) diseases.

Human T-lymphotropic virus type-1 (HTLV-1) belongs to the *Deltaretrovirus* genus of the Orthoretrovirinae subfamily and infects 10–20 million people worldwide. HTLV-1 can be transmitted through sexual contact, intravenous drug use, and breastfeeding from mother to child. The infection is endemic in southwest Japan, the Caribbean, sub-Saharan Africa, South America, with smaller foci in Southeast Asia, South Africa, and northeastern Iran. HTLV-1 was initially isolated in 1980 from two T-cell lymphoblastoid cell lines and the blood of a patient originally thought to have a cutaneous T-cell lymphoma. It was the first human retrovirus ever associated with a human cancer. Three years before the isolation of HTLV-1, a Japanese group reported adult T-cell leukemia (ATL), a rare form of leukemia endemic to southwest Japan, as a distinct clinical entity. In 1981, the same group demonstrated that ATL was caused by a new human retrovirus originally termed 'ATLV'. Later, ATL and HTLV have been shown to be identical, and a single name HTLV-1 has been adopted. In the mid-1980s, epidemiological data linked HTLV-1 infection with a chronic progressive neurological disease, which was termed 'tropical spastic paraparesis (TSP)' in the Caribbean and 'HTLV-1 associated myelopathy (HAM)' in Japan. HTLV-1-positive TSP and HAM were subsequently found to be clinically and pathologically identical and the disease was given a single designation as HAM/TSP. HTLV-1 can cause other chronic inflammatory diseases such as uveitis, arthropathy, pulmonary lymphocytic alveolitis, polymyositis, Sjögren syndrome, and infective dermatitis. Only approximately 2–3% of infected persons develop ATL and another 0.25–4% develop chronic inflammatory diseases, while the majority of infected individuals remain lifelong asymptomatic carriers (ACs). Thus, the viral, host, and environmental risk factors, as well as the host immune response against HTLV-1 infection, appear to regulate in the development of HTLV-1-associated diseases. For over two decades, the investigation of HTLV-1-mediated pathogenesis has focused on Tax, an HTLV-1-encoded viral oncoprotein. Tax activates many cellular genes by binding to groups of transcription factors and coactivators and is necessary and sufficient for cellular transformation. However, recent reports have

identified another regulatory protein, HTLV-1 basic leucine zipper factor (HBZ), that plays a critical role in the development of ATL and HAM/TSP.

HTLV-1-Associated Diseases

Adult T-cell leukemia

ATL is a fatal malignancy of mature CD4+ T cells. It arises in only a small proportion of HTLV-1-infected people (1–5% of infected individuals) after long latency periods following primary infection. ATL shows diverse clinical features, but can be divided into four clinical subtypes: smoldering, chronic, lymphoma, and acute. Each subtype is directly correlated with the prognosis of patients: the smoldering and chronic types are indolent, while the acute and lymphoma types are aggressive and characterized by resistance to chemotherapy and poor prognosis. Development of ATL is characterized by infiltration of various tissues with circulating ATL cells, called 'flower cells', which have conspicuous lobulated nuclei. These cells cause further symptoms including lymphadenopathy, lytic bone lesions, skin involvement, hepatosplenomegaly, and hypercalcemia. Laboratory findings of ATL patients typically reveal a marked leukocytosis, hypercalcemia, high serum levels of lactate dehydrogenase (LDH), and a soluble form of interleukin-2 receptor (IL-2R). In cohort studies of HTLV-1 carriers, the risk factors for ATL appeared to include vertical infection (mother to child transmission), male gender, older age, and increasing numbers of abnormal lymphocytes. Since ATL occurs mainly in vertically infected individuals, but not in those who become infected later in life, the impairment of HTLV-1-specific T-cell responses caused by vertical HTLV-1 infection has been suggested as a possible cause of disease development. The HTLV-1-specific cytotoxic T-cell (CTL) responses from ATL patients are significantly lower than that of HAM/TSP patients. However, insufficient HTLV-1-specific T-cell responses might also occur during and after the onset of ATL. Although ATL has a poor prognosis, recent advances in its treatment have led to significant gains in response rates and

survival. Accumulating evidence suggests that allogeneic bone marrow transplantation and allogeneic peripheral blood stem cell transplantation are potent therapies for aggressive ATL (i.e., the acute and lymphoma type). The combination of the antiretroviral agent zidovudine (AZT) and interferon- α (IFN- α) is also beneficial for overall survival in smoldering and chronic (i.e., indolent) ATL, although its efficacy has not yet been confirmed in well-designed prospective studies.

Since the discovery of HTLV-1, the viral transactivator Tax has been viewed as critical for leukemogenesis, due to its pleiotropic effects on both viral and many cellular genes responsible for cell proliferation, genetic instability, dysregulation of the cell cycle, and apoptosis. However, Tax expression is not detected in about 60% of freshly isolated samples from ATL cases. Recently, the expression of another regulatory protein, HBZ, has been reported in association with all ATL cases. This protein, which is encoded in the minus or antisense strand of the virus genome, promotes proliferation of ATL cells and induces T-cell lymphomas in CD4⁺ T cells by transgenic expression, indicating involvement of HBZ expression in the development of ATL. In addition, among the HTLV-1-encoded viral genes, only the HBZ gene sequence remains intact, unaffected by nonsense mutations and deletion. Thus, HBZ expression is indispensable for proliferation and survival of ATL cells and HTLV-1-infected cells, and Tax expression is not always necessary for the development of ATL.

HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis

HAM/TSP is a chronic progressive myelopathy characterized by spastic paraparesis, sphincter dysfunction, and mild sensory disturbance in the lower extremities. In addition to neurological symptoms, some HAM/TSP cases also exhibit autoimmune-like disorders, such as uveitis, arthritis, T-lymphocyte alveolitis, polymyositis, and Sjögren syndrome. To date, more than 3000 cases of HAM/TSP have been reported in HTLV-1-endemic areas. Sporadic cases have also been described in nonendemic areas such as the United States and Europe, mainly in immigrants from an HTLV-1-endemic area. The lifetime risk of developing HAM/TSP is different among ethnic groups, ranging between 0.25% and 4%. The annual incidence of HAM/TSP is higher among Jamaican subjects than among Japanese subjects (20 vs. three cases/100 000 population), with a 2 to 3 times higher risk for women in both populations. The period from initial HTLV-1 infection to the onset of HAM/TSP is assumed to range from months to decades, a shorter time than for ATL onset. HAM/TSP occurs both in vertically infected individuals and in those who become infected later in life (i.e., through sexual contact (almost exclusively from male to female), intravenous drug use, contaminated blood transfusions, etc.). The mean age at onset is 43.8 years and, like other autoimmune diseases, the frequency of HAM/TSP is higher in women than in men (the male to female ratio of occurrence is 1:2.3).

The essential histopathological feature of HAM/TSP is a chronic progressive inflammation in the spinal cord, predominantly at the thoracic level. The loss of myelin sheaths and axons in the lateral, anterior, and posterior columns is associated with perivascular and parenchymal lymphocytic

infiltration, reactive astrocytosis, and fibrillary gliosis. In addition to HTLV-1 antibody positivity, other laboratory findings of HAM/TSP include the presence of atypical lymphocytes (the so-called flower cells) in peripheral blood and cerebrospinal fluid (CSF), a moderate pleocytosis, and raised protein content in CSF. Oligoclonal bands, raised concentrations of inflammatory markers such as neopterin, tumor necrosis factor (TNF)- α , IL-6 and IFN- γ , and an increased intrathecal antibody synthesis specific for HTLV-1 antigens have also been described in CSF of HAM/TSP patients.

A previous population association study in HTLV-1 endemic in southwest Japan revealed that one of the major risk factors is the HTLV-1 proviral load (PVL), as the PVL is significantly higher in HAM/TSP patients than in ACs. A high PVL was also associated with an increased risk of progression to disease. Higher PVL in HAM/TSP patients than in ACs was also observed in other endemic areas such as the Caribbean, South America, and the Middle East. In southwest Japan, an association was suggested between possession of the HLA-class I genes HLA-A*02 and Cw*08 and a statistically significant reduction in both PVL and the risk of HAM/TSP. By contrast, possession of HLA-class I HLA-B*5401 and class II HLA-DRB1*0101 predisposed patients in the same population to HAM/TSP. Since the function of class I HLA proteins is to present antigenic peptides to CTL, these results imply that individuals with HLA-A*02 or HLA-Cw*08 mount a particularly efficient CTL response against HTLV-1, which may be an important determinant of HTLV-1 PVL and the risk of HAM/TSP.

To date, no generally agreed standard treatment regimen has been established for HAM/TSP, as no treatment for HAM/TSP has proven to be consistently effective and long term. Therefore, current clinical practice for treatment of HAM/TSP is based on case series and open, nonrandomized uncontrolled studies. Although mild to moderate beneficial effects have been reported with corticosteroids, immunosuppressants, high-dose intravenous gammaglobulin, antibiotics (erythromycin and fosfomycin), and vitamin C, the clinical benefits are only transient and limited. The complications of steroid use limit their use particularly in postmenopausal females, who are at higher risk of developing HAM/TSP. Only three randomized placebo-controlled trials have been conducted for HAM/TSP treatment. These studies indicate that IFN- α is an effective therapy, with an acceptable side-effects profile. By contrast, no evidence yet exists of any benefit of zidovudine plus lamivudine for treating HAM/TSP. More clinical trials with adequate power are needed in the future.

Other HTLV-1-Associated Diseases

HTLV-1 has been implicated in the pathogenesis of other inflammatory disorders such as uveitis, arthropathy, infective dermatitis, pulmonary lymphocytic alveolitis, polymyositis, Sjögren syndrome, and autoimmune thyroid diseases, based on the higher HTLV-1 PVL and the higher seroprevalence in patients than in ACs. However, direct evidence for an association between these disorders and HTLV-1 infection is still lacking. Nonetheless, HTLV-1 may be a significant trigger for the development of these autoimmune disorders.

See also: Retroviruses

Further Reading

Blattner WA (ed.) (1990) *Human Retrovirology: HTLV*. New York: Raven Press.

Höllsberg P and Hafler DA (eds.) (1996) *Human T-Cell Lymphotropic Virus Type I*. New York: Wiley.

Sugamura K, Uchiyama T, Matsuoka M, and Kannagi M (eds.) (2003) *Two Decades of Adult T-Cell Leukemia and HTLV-I Research: Gann Monograph on Cancer Research*. Tokyo: Japan Scientific Societies Press.

Elimination of Human T Cell Leukemia Virus Type-1-Infected Cells by Neutralizing and Antibody-Dependent Cellular Cytotoxicity-Inducing Antibodies Against Human T Cell Leukemia Virus Type-1 Envelope gp46

Yuetsu Tanaka,¹ Yoshiaki Takahashi,¹ Reiko Tanaka,¹ Akira Kodama,¹ Hideki Fujii,¹ Atsuhiko Hasegawa,² Mari Kannagi,² Aftab A. Ansari,³ and Mineki Saito⁴

Abstract

Human T cell leukemia virus type-1 (HTLV-1) is prevalent worldwide with foci of high prevalence. However, to date no effective vaccine or drug against HTLV-1 infection has been developed. In efforts to define the role of antibodies in the control of HTLV-1 infection, we capitalized on the use of our previously defined anti-gp46 neutralizing monoclonal antibody (mAb) (clone LAT-27) and high titers of human anti-HTLV-1 IgG purified from HAM/TSP patients (HAM-IgG). LAT-27 and HAM-IgG completely blocked syncytium formation and T cell immortalization mediated by HTLV-1 *in vitro*. The addition of these antibodies to cultures of CD8⁺ T cell-depleted peripheral blood mononuclear cells (PBMCs) from HAM/TSP patients at the initiation of culture not only decreased the numbers of Tax-expressing cells and the production of HTLV-1 p24 but also inhibited the spontaneous immortalization of T cells. Coculture of *in vitro*-HTLV-1-immortalized T cell lines with autologous PBMCs in the presence of LAT-27 or HAM-IgG, but not an F(ab')₂ fragment of LAT-27 or non-neutralizing anti-gp46 mAbs, resulted in depletion of HTLV-1-infected cells. A 24-h ⁵¹Cr release assay showed the presence of significant antibody-dependent cellular cytotoxicity (ADCC) activity in LAT-27 and HAM-IgG, but not F(ab')₂ of LAT-27, resulting in the depletion of HTLV-1-infected T cells by autologous PBMCs. The depletion of natural killer (NK) cells from the effector PBMCs reduced this ADCC activity. Altogether, the present data demonstrate that the neutralizing and ADCC-inducing activities of anti-HTLV-1 antibodies are capable of reducing infection and eliminating HTLV-1-infected cells in the presence of autologous PBMCs.

Introduction

HUMAN T CELL LEUKEMIA VIRUS type-1 (HTLV-1) is the first human retrovirus that was etiologically associated with adult T cell leukemia (ATL) and HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP).¹⁻⁴ HTLV-1 is prevalent worldwide with foci of high prevalence in southwest Japan, the Caribbean islands, South America, and a part of Central Africa. The total number of HTLV-1 carriers is currently estimated to be 10–20 million.⁵ The majority of HTLV-1 carriers remain asymptomatic throughout their lives, and approximately 5% of HTLV-1-infected individuals will develop either ATL or HAM/TSP after prolonged latency periods.

HTLV-1 is transmitted through contact with bodily fluids containing infected cells most often from mother to child through breast milk or via blood transfusion. It has been previously established that HTLV-1 efficiently spreads from cell to cell via the formation of virological synapses.⁶ More recently, however, the formation of extracellular HTLV-1 viral particles similar to the formation of bacterial films has also been shown to be effective in viral transmission.⁷ HTLV-1-antigen-expressing cells are difficult to detect at least in fresh peripheral blood mononuclear cells (PBMCs) from HTLV-1-infected individuals.⁸ However, when these PBMCs are isolated from the blood and cultured *in vitro*, some T cells begin to produce HTLV-1 antigen^{9,10} followed by spontaneous immortalization of the cells in media containing interleukin-2 (IL-2).¹¹

¹Department of Immunology, Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan.

²Department of Immunotherapeutics, Graduate School, Tokyo Medical and Dental University, Tokyo, Japan.

³Department of Pathology, Emory University School of Medicine, Atlanta, Georgia.

⁴Department of Microbiology, Kawasaki Medical School, Okayama, Japan.

Although it has been suggested that HTLV-1 can stay dormant in infected cells and become resistant to immune effector mechanisms by ratcheting down its antigen production,¹² the continued presence of strong CD8⁺ cytotoxic T lymphocyte (CTL) responses¹³ and readily detectable levels of antibodies specific for HTLV-1 antigens in HTLV-1-infected people¹⁴ indicates that persistent production of HTLV-1 must occur *in vivo* to maintain such effector mechanisms. Escape from immune effector mechanisms by spontaneous mutation of key residues is unlikely, due to the high degree of genomic stability that is characteristic of the HTLV-1 genome.¹⁵ It has been suggested that HTLV-1-infected cells expressing HTLV-1 antigens occur at a low enough frequency that they are constantly being eliminated by HTLV-1-specific CTL *in vivo*¹⁰ without leading to immune exhaustion. Besides CTL and virus neutralizing antibodies, there has been renewed interest in the potential role of antibody-dependent cellular cytotoxicity (ADCC) as an effector mechanism against a number of viral infections. This view has been highlighted by the recent demonstration of the potential role of ADCC in the only known partially successful human RV144 trial of a vaccine against human immunodeficiency virus type-1 (HIV-1).¹⁶ The ADCC activity against HTLV-1 was first reported by Miyakoshi *et al.* in 1984¹⁷ followed by a number of other reports.^{18–21}

So far, several lines of evidence show that the HTLV-1 envelope gp46 antigen serves as a major target of ADCC.^{22–24} Antibodies against gp46 antigen are commonly detected in the sera of HTLV-1-infected individuals.^{25–27} However, the precise role of ADCC effector mechanism(s) in controlling HTLV-1 infection has been lacking. A possible involvement of anti-HTLV-1 antibodies in the suppression of spontaneous HTLV-1 antigen expression by HTLV-1-infected cells was first reported by Tochikura *et al.*²⁸ These investigators showed that serum IgG from HTLV-1-infected donors interfered with HTLV-1 antigen expression by *in vitro*-cultured PBMCs from both ATL patients and healthy HTLV-1 carriers. However, the precise mechanism by which this was mediated remained unclear.

In efforts to define the role of antibodies with neutralizing and ADCC-inducing activities in the control of HTLV-1 infection, we capitalized on the use of our previously defined rat anti-gp46 neutralizing monoclonal antibody (mAb) (LAT-27)²⁹ and pooled human anti-HTLV-1 IgG purified from HAM/TSP patients (HAM-IgG). Studies were conducted to evaluate the potential of these antibodies to block HTLV-1 infection and eliminate HTLV-1-infected cells from autologous T cell cultures that had previously been infected with HTLV-1 *in vivo* or *in vitro*. Results of these studies show that monoclonal LAT-27 and the polyclonal HAM-IgG are not only capable of mediating neutralization and ADCC, but are also highly effective in the elimination of HTLV-1-infected cells in the presence of fresh autologous PBMCs while preventing *de novo* infection with HTLV-1.

Materials and Methods

Reagents

The medium used throughout was RPMI 1640 medium (Sigma-Aldrich, Inc., St. Louis, MO) supplemented with

10% fetal calf serum (FCS), 100 U/ml of penicillin, and 100 µg/ml of streptomycin (hereinafter called RPMI medium). Anti-human CD3 (clone OKT-3) and anti-CD28 (clone 28.2) mAbs were purchased from the American Type Culture Collection (Rockville, MD) and Biologend (San Diego, CA), respectively.

The rat and mouse mAbs utilized in the studies reported herein were produced and characterized by our laboratory previously.^{29–34} These antibodies were rat IgG2b anti-gp46 (clones LAT-27 and LAT-25), rat IgG2a anti-gp46 (clone LAT-12), rat IgG2b anti-HCV (clone Mo-8), rat IgG2a anti-HTLV-1 p24 (clone WAG-24), mouse IgG1 anti-HTLV-1 gp46 (clone MET-3), mouse IgG3 anti-HTLV-1 Tax (clone Lt-4), mouse IgG1 anti-p24 (clone NOR-1), and mouse IgG1 anti-HIV-1 p24 (clone 2C2). These in-house mAbs were purified from the ascites fluids of groups of CB.17-SCID mice carrying the appropriate hybridoma cell line. The ascites fluid was subjected to ammonium sulfate precipitation followed by gel filtration using Superdex G-200 (GE Healthcare, Tokyo, Japan). Aliquots of these mAbs were labeled with either fluorescein isothiocyanate (FITC), Alexafluor 488, Alexafluor 647, HRP (Dojindo, Kumamoto, Japan), or Cy-5 (GE Healthcare) according to the manufacturer's instructions. The FITC- or phycoerythrin (PE)-labeled mouse mAbs against human CD3, CD4, CD8, CD14, CD16, CD19, or CD56 and unlabeled mouse anti-CD16 and anti-CD32 mAbs were purchased from Abcam.

For cell depletion, magnetic beads labeled with anti-CD4, CD8, CD14, CD16, CD19, and antimouse IgG (Dyna) and those labeled with anti-CD56 mAb (LifeTec) were used according to the manufacturer's recommendations. Mitomycin-C (MMC) was commercially purchased from Kyowa Kirin (Tokyo, Japan) and used at 50 µg/ml in RPMI medium. A purified F(ab')₂ fragment of LAT-27 IgG generated by enzymatic digestion of LAT-27 IgG was purchased from IBL Inc. (Gunma, Japan). Human IgG was purified from pooled plasma from three normal donors (normal IgG) and three HAM patients (HAM-IgG) using protein-G affinity purification kits (GE Healthcare).

The protocols for the use of human PBMCs and animals were approved by the Human IRB and the Institutional Animal Care and Use Committee (IACUC) on clinical and animal research of the University of the Ryukyus prior to initiation of the present study.

Cell cultures

PBMCs were isolated from heparinized blood by standard density gradient centrifugation using Lympholyte (Cedarlane, Burlington, Canada). Some PBMCs were cryopreserved using a cell freezing media (Cell reservoir, Nakarai Tesque Inc., Kyoto, Japan). The method to activate PBMCs with anti-CD3 and CD28 mAbs has been described previously.³⁴ The HTLV-1-producing T cell lines utilized included MT-2, HUT102, IL-2-dependent CD4⁻CD8⁺ ILT-M1 cells derived from an HAM/TSP patient, CD4⁺CD8⁻ ILT-H2 cells, ATL-3 cells derived from ATL patients, and a number of other T cell lines derived from normal PBMCs following *in vitro* immortalization by cocultivation with MMC-treated ILT-M1 cells. These cell lines were maintained in culture using RPMI medium containing 20 U/ml IL-2.

The syncytium inhibition assay was performed using an assay that involved the coculture of ILT-M1 and Jurkat cells.³⁵ A suspension of ILT-M1 cells in a volume of 25 μ l containing 5×10^4 cells in 20 U/ml IL-2 media was mixed with 50 μ l of serially diluted antibody to be tested in a flat-bottom 96-well microtiter plate for 5 min followed by the addition of 5×10^4 Jurkat cells in a volume of 25 μ l of medium. After coculture for 18~24 h at 37°C in a 5% CO₂ humidified incubator, syncytium formation was microscopically observed using an inverted microscope and the minimum concentration of antibody that showed complete blocking of syncytium formation was determined. In some experiments, gp46 antigen that had been affinity purified from the culture supernatants of MT-2 cells using our anti-gp46 mAb (MET-3) antibody-coupled Sepharose 4B column (GE Healthcare) was used as a target antigen to serve as a specificity control to block the syncytia neutralization of antibodies.³⁶

The HTLV-1-immortalization inhibition assay was performed according to the method described previously with a slight modification.²⁹ Briefly, PBMCs from HTLV-1-negative healthy donors were activated with immobilized OKT-3 together with soluble anti-CD28 mAb overnight, and these cells (5×10^4 cells) were cocultured with an equal number of MMC-treated ILT-M1 cells in wells of round-bottom 96-well microtiter plates (BD) in 0.2 ml media containing 20 U/ml IL-2 at 37°C in a humidified 5% CO₂ incubator in the presence or absence of the test antibodies. The medium was replaced with fresh IL-2-containing media with or without antibody every 3–5 days. Aliquots of the cocultured cells were monitored every week for intracellular expression of Tax antigen, and the culture supernatants were monitored for the production of p24.

The assay for inhibition of spontaneous HTLV-1 antigen expression in PBMCs from HAM/TSP patients was performed as follows. PBMCs from HAM/TSP patients after depletion of CD8⁺ cells were cultured *in vitro* at 1×10^6 cells/ml in 20 U/ml IL-2-containing RPMI medium at 37°C in a 24-well plate (BD) in the presence of various anti-HTLV-1 mAbs, HAM-IgG, or controls. After 24 h, cells were harvested and an aliquot stained with anti-CD3, CD4, or CD8 mAb, followed by fixation and subsequent intracellular Tax staining. The frequency and absolute cell numbers of Tax-positive cells were analyzed by flow cytometry (FCM) using the Flowcount (Coulter). The remaining cells were further cultured for 2~6 weeks with a change of media with or without antibody every 3~4 days. If necessary, cultures were split into 1:2 or 1:4.

The elimination of HTLV-1 antigen-expressing cells was tested as follows. The IL-2-dependent HTLV-1-infected T cell lines established from PBMCs of normal donors (2×10^5 cells/ml) were cocultured with autologous fresh PBMCs (2×10^6 cells/ml) in 20 U/ml IL-2-containing RPMI medium in triplicate in a round-bottom 96-well microtiter plate (BD) in the presence or absence of various antibodies. After initial coculture for 3 days, these cultures were split, and one was cultured in the presence and the other in the absence of fresh PBMCs and antibodies for 3 days. If necessary, these cells were further treated with antibodies and fresh PBMCs every 3 days. These cell cultures were periodically monitored for changes in the levels of Tax-expressing cells and levels of p24 production.

Flow cytometry (FCM) and enzyme-linked immunosorbent assay (ELISA)

For the detection of HTLV-1 antigen-expressing cells, sample cells were analyzed using polychromatic FCM. Briefly, live cells were Fc receptor-blocked with 2 mg/ml pooled normal human IgG in FACS buffer [phosphate-buffered saline (PBS) containing 0.2% bovine serum albumin (BSA) and 0.1% sodium azide] for 10 min on ice, and prestained with fluorescent dye-labeled mAbs for 30 min. After washing with FACS buffer, the cells were fixed in 4% paraformaldehyde (PFA) in PBS for 5 min at room temperature followed by permeabilization and washing in 0.5% saponin+1% BSA (Sigma) containing FACS buffer. The cells were incubated with 0.1 μ g/ml of Cy5-labeled anti-Tax antibody (clone Lt-4) for 30 min. Negative control cells were stained with Cy5-Lt-4 in the presence of 50 μ g/ml of unlabeled Lt-4. These cells were analyzed using a FACSCalibur (BD) and the data obtained were analyzed using the Cell Quest software (BD). Typical staining of HTLV-1-infected T cell lines with Lt-4 and LAT-27 is also shown in Supplementary Fig. S1 (Supplementary Data are available online at www.liebertpub.com/aid).

Production of HTLV-1 was determined by the measurement of the HTLV-1 core p24 antigen levels in the culture supernatants using our in-house formulated and standardized ELISA kit using a pair of anti-HTLV-1 p24 mAbs. The sensitivity of this assay was determined to be 0.5 ng/ml of p24 (data not shown).

ADCC assay

HTLV-1-immortalized target cells from healthy donors were labeled with ⁵¹Cr for 60 min as described previously³⁷ and mixed with varying ratios of fresh PBMCs (varying effector-to-target cell ratios) in the presence or absence of various antibodies for the indicated period of time in 20 U/ml IL-2-containing medium. Appropriate controls were included with each assay including target cells cultured in media alone (spontaneous release) and in 0.5 N HCl (100% release). After brief centrifugation, supernatants were harvested and ⁵¹Cr activity in each sample was determined using a gamma counter. The net percentage ⁵¹Cr release was calculated using standard methods as follows (cpm in experiment – cpm in medium)/(cpm in 0.5 N HCl – cpm in medium) \times 100. In some experiments, PBMCs were depleted of CD4⁺, CD8⁺, CD14⁺, CD16⁺, CD19⁺, or CD56⁺ cells using appropriately conjugated immunomagnetic beads and tested for their effector activity.

Statistical analysis

Data were tested for statistical significance by the Student's *t* test using Prism software (GraphPad Software).

Results

HTLV-1 neutralizing activities of LAT-27 and human anti-HTLV-1-IgG *in vitro*

The syncytium inhibition assay has been generally used to evaluate HTLV-1 neutralization titers of anti-HTLV-1

antibodies. To optimize the syncytium inhibition assay, we screened various coculture combinations of HTLV-1-producing cells with a variety of HTLV-1-negative target cells, and selected the HTLV-1-producing T cell line ILT-M1 and the HTLV-1-negative T cell line Jurkat. Overnight coculture of the ILT-M1 and Jurkat cells resulted in the generation of numerous large syncytia (Fig. 1). Using this assay system, we titrated the syncytia-blocking activity of monoclonal LAT-27 and polyclonal IgG purified from pooled plasma from HAM patients (HAM-IgG). HAM-IgG was used as a positive anti-HTLV-1 antibody control because it contained high titers of antibodies against HTLV-1 antigens (Supplementary Fig. S2). The minimum concentrations required for the “complete” inhibition of syncytia formation by LAT-27 and HAM-IgG antibodies were calculated to be 5 $\mu\text{g/ml}$ and 50 $\mu\text{g/ml}$, respectively (Supplementary Fig. S3). To adjust for decay in antibody activities during cultivation at 37°C, we used LAT-27 and HAM-IgG at concentrations of 10 and 100 $\mu\text{g/ml}$, respectively, in all subsequent experiments.

To confirm the gp46 specificity of LAT-27 and HAM-IgG in this syncytium inhibition assay, an affinity-column-purified gp46 antigen³⁶ was added to an aliquot of either LAT-27 or HAM-IgG solution prior to cocultivation. Controls consisted of incubating an aliquot of the cocultures in media alone (shaded bars denoted by 0) or media containing 10 $\mu\text{g/ml}$ of gp46 (dark bars also denoted by 0). As shown in Fig. 2, HAM-IgG incubated in media alone clearly inhibited syncytia formation in a dose-dependent manner (at 12.5~100 $\mu\text{g/ml}$). However, preincubation of the HAM-IgG at 12.5~100 $\mu\text{g/ml}$ with 10 $\mu\text{g/ml}$ of affinity-purified gp46 resulted in significant reversal of inhibition, suggesting that gp46 was the main target for the neutralization activity present in the human anti-HTLV-1 antibodies. Similar results were obtained when LAT-27 instead of HAM-IgG was preincubated with gp46 (data not shown).

LAT-27 as reported previously²⁹ and HAM-IgG completely inhibited HTLV-1-mediated T cell immortalization of

normal activated T cells *in vitro* at concentrations of 10 $\mu\text{g/ml}$ and 100 $\mu\text{g/ml}$, respectively (Fig. 3).

Effect of antibodies on spontaneous HTLV-1 antigen expression in vitro

To evaluate the role of anti-gp46 neutralizing antibodies against T cells carrying endogenous HTLV-1 from naturally infected donors, we cultured freshly isolated PBMCs from HAM/TSP patients in the presence or absence of various antibodies for 24 h. To exclude any potential effects of CD8⁺ CTL that are present within the PBMCs from the HAM/TSP patients,¹⁰ PBMCs were depleted of CD8⁺ T cells prior to the assay. For quantitation of the frequencies of HTLV-1 antigen-expressing cells, we stained an aliquot of the cells for the expression of intracellular Tax antigen utilizing our standardized anti-Tax mAb, which has generally been used to detect HTLV-1-infected cells.^{10,38} At a concentration of 10 $\mu\text{g/ml}$, LAT-27 reduced the frequency of Tax⁺ cells (Fig. 4A). This reduction was antigen and epitope specific since neither the isotype control rat IgG2b mAb (anti-HCV envelope) nor the anti-gp46 nonneutralizing mAb (LAT-25) and the other anti-gp46 nonneutralizing mAbs (clones LAT-12 and MET-3) that compete with LAT-27 in an antibody binding assay showed any detectable inhibitory effect (data not shown). The reduction in the frequency of Tax⁺ cells by LAT-27 was partially reversed by a mixture of anti-CD16 and anti-CD32 mAbs when added at the initiation of the assay, suggesting an involvement of Fc receptors in this reduction assay.

As shown in Fig. 4B, after prolonged culture (2 weeks) the suppressive effect of LAT-27 became more evident since there remained few if any Tax⁺ cells in the LAT-27-treated cultures of PBMCs from each of the HAM patients tested. A similar suppressive effect was observed for HAM-IgG but not normal human IgG (Fig. 4B). It should be noted that in the present culture conditions, similar to what has been generally observed for the PBMC cultures from HTLV-1-infected




FIG. 1. Human T cell leukemia virus type-1 (HTLV-1)-mediated syncytia formation. HTLV-1⁺ ILT-M1 and HTLV-1⁻ Jurkat cells were either cultured alone or cocultured at a cell-to-cell ratio of 1:1 in the presence or absence of 10 $\mu\text{g/ml}$ LAT-27 for 18 h. Syncytia were microscopically observed using an inverted microscope at a magnification of 100 \times . Representative data from three independent experiments are shown.





FIG. 2. Anti-gp46 antibodies are major HTLV-1 neutralizing antibodies in HAM-IgG. HAM-IgG at graded concentrations (0~100 $\mu\text{g/ml}$) was preincubated with either affinity-purified gp46 antigen (black bars) at 10 $\mu\text{g/ml}$ for 10 min or incubated with medium alone (gray shaded bars, labeled as “gp46-”) and tested for syncytia inhibition activity. The numbers of syncytia were manually counted using a “Burker-Turk” hemocytometer. Representative data from three independent experiments are shown.

donors, the frequency of Tax⁺ cells gradually decreased during 2 weeks in culture even in IL-2 medium alone and thus it was not likely due to an effect of the addition of the control rat isotype IgG or normal IgG. Spontaneous immortalization of T cells by HTLV-1 was observed in the PBMC cultures from two-thirds of the HAM patients treated with medium

FIG. 3. LAT-27 and HAM-IgG completely block HTLV-1-mediated T cell immortalization *in vitro*. Activated peripheral blood mononuclear cells (PBMCs) from normal donors were seeded into six wells of 96-well U-bottom plates (1×10^5 cells/0.1 ml/well) and cocultured with an equal number of mitomycin C-treated ILT-M1 cells in the presence or absence of 10 $\mu\text{g/ml}$ of LAT-27 or rat isotype control, 100 $\mu\text{g/ml}$ of normal human IgG, or HAM-IgG. Half of the medium was replaced every 3~5 days with new similar fresh media, and if necessary, cultures were split into 1:2. Each data point reflects the frequency of Tax⁺ cells or the levels of p24 in the culture supernatants of each well 6 weeks after culture. Data shown are representative of three independent experiments. The differences between the controls and the experimental data were highly significant, denoted as $**p < 0.01$. The negative control used for LAT-27 was an isotype control (rat IgG2b anti-HCV).



alone, isotype control, or normal IgG, but not in those treated with LAT-27 or HAM-IgG, as judged 6 weeks after culture (data not shown).

Importantly, neither LAT-27 nor HAM-IgG (data not shown) showed any detectable blocking effects on HTLV-1 Tax expression (Fig. 5) and p24 antigen production (data not shown) in long-term cultured HTLV-1-infected cell lines. It is known that the levels of Tax-positive cells vary depending on the cell lines being utilized due to DNA methylation, hypoacetylation of histones, or epigenetic changes of provirus.³⁹ Thus, we reasoned that the addition of the neutralizing antibodies blocks *de novo* expansion of HTLV-1 infection and/or eliminates the HTLV-1 gp46 expressing T cells via an FcR-dependent pathway in combination with effector cells contained within the PBMCs.

FcR-dependent elimination of HTLV-1-infected cells by antibodies

Due to the limitations on the availability of PBMC samples from HAM/TSP patients, we established a number of IL-2-dependent HTLV-1-infected CD4⁺ T cell lines from PBMCs of normal donors to determine whether ADCC was involved in the suppression of HTLV-1-infected cells. These HTLV-1⁺CD4⁺ T cell lines were cocultured with autologous fresh PBMCs in the presence or absence of various antibodies including F(ab')₂ of LAT-27, which showed HTLV-1 neutralization at a minimum concentration of 2.5 $\mu\text{g/ml}$ (data not shown). HAM-IgG was included as an ADCC-positive control. After 3 days in culture, these cells were stained for cell surface CD4 and intracellular Tax antigen, and analyzed on a gated population of cells that displayed high forward and side scatters, which included a majority of the HTLV-1-infected




FIG. 4. Reduction of Tax-expressing cells in *in vitro* cultures of PBMCs from HAM patients in the presence of HTLV-1 neutralizing monoclonal antibody (mAb). (A) PBMCs from HAM patients were depleted of CD8⁺ T cells and cultured *in vitro* for 24 h at 1×10^6 cells/ml in interleukin (IL)-2-containing medium in the presence or absence of 10 μ g/ml antibodies indicated in the figure. The cells were then stained for cell surface CD4 and intracellular Tax antigen as described in the Materials and Methods section. The numbers in each dot-plot show the percentage of CD4⁺ Tax⁺ cells. The mixture of antibodies against human Fc receptors (FcR) (anti-CD16 and CD32) was added to block FcR function. Data shown are representative of three independent experiments using PBMCs from different donors. (B) PBMCs from HAM patients ($n=8$) were depleted of CD8⁺ T cells and cultured *in vitro* in IL-2-containing medium in the presence of (1) LAT-27 or an isotype control mAb at 10 μ g/ml or (2) HAM-IgG or normal human IgG at 100 μ g/ml for 2 weeks. The cells were stained for Tax antigen and the total percentage of Tax⁺ cells was calculated. The control used for LAT-27 was an isotype control (rat IgG2b anti-HCV mAb). The negative control mAb for anti-CD16 and CD32 was mouse IgG1 against HIV-1 (clone 2C2).

CD4⁺ T cells but not normal PBMCs. However, no detectable reduction of Tax⁺ cells was observed in the cultures treated with either LAT-27 or HAM-IgG cocultured in the presence of PBMCs (data not shown). Thus, these cells were washed and cocultured again for an additional 3 days with the same antibodies and fresh PBMCs.

As shown in Fig. 6A, although fresh PBMCs alone reduced the frequency of Tax⁺ cells to some extent, a marked net reduction was seen in the presence of LAT-27 and HAM-IgG. In a similar fashion, the production of HTLV-1 p24 in the culture supernatants was markedly reduced by LAT-27 and HAM-IgG in the presence of autologous PBMCs. As shown in Fig. 6B, when these cultures were exposed one more time to the same antibodies and fresh PBMCs, LAT-27 IgG and HAM-IgG, but not F(ab')₂ of LAT-27 or normal IgG, further reduced the frequency of Tax⁺ cells. These data suggest that the addition of LAT-27 as well as HAM-IgG eliminates the HTLV-1 gp46 antigen-expressing cells via an FcR-dependent manner while blocking the spread of HTLV-1 to new target cells including fresh PBMCs in the same cell cultures *in vitro*. The involvement of complement-dependent

cytotoxicity was ruled out because the fetal calf serum used in the present study was heat inactivated prior to use.

ADCC against HTLV-1-infected cells by LAT-27

To examine whether LAT-27 could mediate ADCC in the present culture conditions, IL-2-dependent HTLV-1-infected T cells established from normal donors were labeled with ⁵¹Cr and cocultured with fresh autologous PBMCs in the presence or absence of antibodies. Significant ADCC activity was induced by HAM-IgG, but not LAT-27, by 6 h (data not shown). However, after 24 h at a high effector-to-target cell ratio, LAT-27, but not the F(ab')₂ fragment of LAT-27, showed significant cytotoxicity ($p < 0.01$) (Fig. 7A). When the effector PBMCs were depleted of either CD16⁺ or CD56⁺ cells, but not CD14⁺ or CD19⁺ cells, the ADCC activity mediated by either LAT-27 or HAM-IgG was significantly reduced ($p < 0.01$) (Fig. 7B and C). These data suggest that the CD16⁺ CD56⁺ subpopulation of PBMCs [representing natural killer (NK) cells] were most likely the main effector cells involved in the cell lysis. These results




FIG. 5. LAT-27 alone does not affect long-term cultured HTLV-1-infected T cells. A standard HTLV-1-infected cell line HUT-102 (HUT), an IL-2-dependent CD4⁺ T cell line (ATL-3, generated from an ATL patient), and an IL-2-dependent CD8⁺ T cell line (ILT-M1) were cultured in the presence of 10 μ g/ml of either LAT-27 or isotype control (control) for 4 days, and the frequencies of Tax⁺ cells were determined by flow cytometry ($n = 3$).

demonstrate that the monoclonal LAT-27, similar to the polyclonal HAM-IgG, is able to induce ADCC against HTLV-1-infected cells by autologous NK cells while protecting the spread of new infection with HTLV-1.

Discussion

The present study demonstrates that the monoclonal anti-HTLV-1 gp46 antibody clone LAT-27 generated by our laboratory mediates both HTLV-1 neutralization and HTLV-1-specific ADCC, and such ADCC activity might be capable of eliminating HTLV-1-infected T cells *in vitro* in the presence of autologous fresh PBMCs. Although fresh PBMCs alone showed a partial but significant inhibitory activity against HTLV-1-infected cells during prolonged *in vitro* cultivation, the data obtained here suggest that the HTLV-1-specific ADCC activity is the direct mechanism for this eradication. Similar suppressive activities were demonstrated for human IgG from HAM patients. This mechanism may explain the previous findings reported by Tochikura *et al.*²⁸ on the HTLV-1 suppressing activity of human anti-HTLV-1 antibodies. Furthermore, this mechanism may also explain in part why HTLV-1 antigen-expressing cells are not found *in vivo* in anti-HTLV-1 antibody-positive individuals. Although it is not known where and when HTLV-1 is produced *in vivo* in the infected individual, the continued presence of CD8⁺ T cells and antibodies specific for HTLV-1 indicates that HTLV-1 should be expressed periodically. Based on the results presented in this article, it might be possible that HTLV-1 expression occurs upon T cell stimulation in the periphery, but as soon as the cells express HTLV-1 gp46 antigen they might be instantly killed by the combination of anti-HTLV-1 ADCC-inducing antibodies and activated NK cells.

We submit that the addition of fresh PBMCs to the autologous HTLV-1-producing T cell cultures may result in it becoming readily infected and immortalized by HTLV-1. Thus, it is clear that the presence of neutralizing antibody is essential for the prevention of new infection of PBMCs and since ADCC effector mechanisms are functional during this time period, their contribution to the control of infection deserves merit. Interestingly, the ADCC induced by LAT-27 progressed slowly and the elimination of Tax⁺ cells became evident only after two consecutive exposures every 3 days in the present cell culture conditions. Since there was heterogeneity of the intensity of gp46 expression among cells in a single HTLV-1-infected cell line (data not shown), the findings suggest that the lysis of such gp46^{low} cells by ADCC requires a prolonged incubation period. Alternatively, since the repeated exposure against PBMCs resulted in an accumulation of live PBMCs, it is possible that a large number of effector fresh PBMCs might be required for the complete eradication by LAT-27, possibly due to the relatively low affinity of LAT-27 for human FcR.

Cell depletion experiments in the present study showed that the effector cells involved in the HTLV-1-specific ADCC in fresh PBMCs were either CD16⁺ or CD56⁺ cells, representing the cytolytic human NK cell subset, although it remains to be confirmed with purified NK cells. Because there are abundant circulating NK cells in the periphery in healthy donors, these findings strongly suggest that the HTLV-1-specific ADCC responses in the presence of neutralizing antibodies might have a role in controlling HTLV-1 *in vivo* in concert with HTLV-1-specific CTL responses in healthy HTLV-1 carriers. This view is supported by the findings that the ADCC effector function of PBMCs is lower in both HAM/TSP and ATL patients than healthy HTLV-1 carriers or normal donors,^{17,40} suggesting that defects in functional ADCC activities may contribute to the onset of HTLV-1-related diseases.

The level of ADCC of HTLV-1⁺ cells by LAT-27 was weaker than that induced by human polyclonal anti-HTLV-1 IgG. This might be due to the fact that LAT-27 is of rat origin and recognizes a single epitope on the gp46 (amino acids 191–196)²⁹ in contrast to the fact that HAM-IgG is of human origin and consists of high titers of polyclonal antibodies against multiple epitopes on gp46. In addition, it has been shown that mouse and rat IgG exhibit different ADCC activities with human NK cells depending on their subclasses, and that rat IgG2b (the subclass of LAT-27), but not IgG2a, triggers effective ADCC with human NK cells.⁴¹ Along these lines, it is possible that a humanized form of LAT-27 utilizing the human IgG1- or IgG3-Fc portion as a backbone would be far more effective than even the rat IgG2b of LAT-27.

This hypothesis has been confirmed by preliminary experiments using humanized LAT-27 consisting of human IgG1, which was generated in collaboration with Dr. Shimizu of IBL Inc. (Tanaka *et al.*, unpublished observations). In addition, epitope specificity and/or the affinity of anti-gp46 antibodies may also be involved in determining the ADCC-inducing activities. For example, LAT-25, which belongs to the rat IgG2b subclass and recognizes a C-terminal region of the gp46, did not eradicate HTLV-1⁺ cells (Fig. 7). Similarly, Kuroki *et al.* showed that a human mAb recognizing gp46 amino acids 191–196 (similar to the epitope recognized by LAT-27) could induce ADCC, but another human mAb




FIG. 6. Elimination of Tax⁺ cells and reduction of HTLV-1 p24 production in IL-2-dependent HTLV-1-infected T cells cocultured with autologous PBMCs in the presence of LAT-27 or HAM-IgG. (A) IL-2-dependent CD4⁺ HTLV-1-infected T cells established from the PBMCs of normal donors were repeatedly exposed to autologous PBMCs (+PBMCs) in the presence of 10 μ g/ml of LAT-27 or isotype control, or 100 μ g/ml of HAM-IgG, or normal human IgG twice at 3 day intervals. Two days after the second exposure, the high forward and side scatter gated populations of cells that contained a majority of the HTLV-1⁺ cells but not PBMCs were analyzed for the frequencies of CD4⁺ Tax⁺ cells. Percentages of CD4⁺ Tax⁺ cells are shown in the upper right quadrant. The numbers in parentheses show the levels of HTLV-1 p24 produced in the culture supernatants. Data shown are representative of three independent experiments using PBMCs from different donors. (B) As shown in (A), IL-2-dependent CD4⁺ HTLV-1-infected T cells were cultured *in vitro* either alone (control) or exposed to autologous PBMCs (P+) in the presence of 10 μ g/ml of LAT-27 or F(ab)₂ LAT-27, or 100 μ g/ml of normal human or HAM-IgG in triplicate wells with three supplementations provided at 3 day intervals. Two days after the third exposure, the cells were examined for the frequencies of CD4⁺ Tax⁺ cells. Data shown are representative of three independent experiments using HTLV-1-infected cells and PBMCs from different donors.

recognizing the gp46 amino acids 187–193 could not, even though the two mAbs bind similarly to the cell surface of HTLV-1-infected cells and belong to the ADCC-inducing human IgG1.²²

It remains to be determined whether there are clonal populations of human IgGs that can mediate both the neutralization and ADCC against HTLV-1. So far, it has been shown that the two activities could be operating separately by different epitope-specific human mAbs against gp46.²² Recently, Kuo *et al.*²⁴ showed that both neutralizing and non-neutralizing mouse anti-gp46 mAbs can activate neutrophils and mediate its burst activity in the presence of an HTLV-1-infected MT-2 cell line, and concluded that HTLV-1-specific ADCC capacity is not coupled to the neutralizing capacity of the antibody. Thus, these articles highlight the finding of LAT-27 as a special antibody. Analyses of the conformational and antigenic structure of gp46 expressed on the cell surface will be necessary to address this issue further.

Another possible target for ADCC on HTLV-1-expressing cells is the envelope gp21; however, it has been unclear

whether human anti-gp21 antibodies function in ADCC. In addition, the recent finding that the glycosylation of Fc-IgG plays an important role in anti-HIV-1 ADCC effector mechanisms⁴² suggests that this issue needs to also be considered in the evaluation of anti-HTLV-1 gp46 antibodies and for vaccine formulations in general. Nevertheless, it is clear that the simultaneous operation of neutralization and ADCC by single or polyclonal antibodies is essential to recognize and eliminate HTLV-1⁺ cells since not only T cells but also the NK cells are permissive to HTLV-1 infection.⁴³

The present study also showed that fresh PBMCs had a partial and significant but not complete suppressive activity against autologous HTLV-1-infected cells in the absence of anti-HTLV-1 antibodies. Our preliminary experiments indicate that monocytes might be involved in this partial suppression because PBMCs depleted of CD14⁺ cells, but not of NK cells, were no longer suppressive in the absence of LAT-27 (data not shown). Since HTLV-1-infected T cells are continuously activated due to the Tax antigen, one possible mechanism is a monocyte-dependent cell death (MDCD)




FIG. 7. The CD16⁺ CD56⁺ PBMCs mediate antibody-dependent cellular cytotoxicity (ADCC) in the presence of LAT-27 or HAM-IgG. (A) ⁵¹Cr-labeled HTLV-1-infected cells were cocultured *in vitro* with autologous fresh PBMCs at various E/T ratios in the presence or absence of 10 μg/ml of LAT-27 or F(ab')₂ LAT-27, or 100 μg/ml of normal human or HAM-IgG for 24 h. Each coculture was performed in triplicate, and the amount of radioactivity in the culture supernatants was determined. Data shown are representative of three independent experiments. (B, C) Effector PBMCs before or after depletion of CD14⁺, CD16⁺, CD19⁺, or CD56⁺ cells were assayed for ADCC activity against autologous HTLV-1-infected cells in the presence of LAT-27 (10 μg/ml) or HAM-IgG (100 μg/ml) in triplicate wells in the 24 h ⁵¹Cr-release assay. Data shown are representative of two independent experiments.

against activated autologous T cells.⁴⁴ Further studies are in progress to address this mechanism.

Based on the data presented herein, it is suggested that humanized LAT-27 mAb might have potential as a passive vaccine against HTLV-1 infection for HTLV-1-uninfected individuals at high risk of HTLV-1 infection, including babies born to HTLV-1 carriers and drug abusers who are also at high risk of HIV infection, and for HTLV-1 carriers whose anti-HTLV-1 neutralizing and ADCC-inducing antibody titers are low. One concern is the potential interference of LAT-27 activity by other nonneutralizing or non-ADCC-inducing antibodies that may interfere with the binding of LAT-27 to gp46. We have performed some experiments and obtained data showing that LAT-12, which blocked the binding of LAT-27 to HTLV-1-infected cells, did not interfere with either LAT-27-mediated syncytium blocking²⁹ and/or the eradication of HTLV-1-infected cells with autologous PBMCs (Supplementary Fig. S4). It seems likely that the binding affinities of neutralizing antibodies to gp46 expressed on actively living cells are higher than those of nonneutralizing antibodies. Thus, validation of humanized LAT-27 in animal models is currently one of our objectives.

Acknowledgments

This work was supported by grants from the Ministry of Education, Culture, Sports, Science, and Technology and the Ministry of Health, Labor, and Welfare of Japan.

Y.Tak. and A.H. carried out the ADCC assays. R.T. and A.K. produced, purified, labeled monoclonal antibodies, confirmed their specificities, and made in-house EILSA for p24. M.S. participated in the determination of proviral loads and performed the statistical analysis. M.K. established HTLV-1-infected cells from patients and participated in the design of the study. A.A.A. participated in the design of the study and helped to draft the manuscript. Y.T. conceived the study, participated in its design and coordination, carried out the coculture assays, and drafted the manuscript. All authors read and approved the final manuscript.

Author Disclosure Statement

No competing financial interests exist.

References

- Poiesz BJ, Ruscetti FW, Reitz MS, Kalyanaraman VS, and Gallo RC: Isolation of a new type C retrovirus (HTLV) in primary uncultured cells of a patient with Sezary T-cell leukaemia. *Nature* 1981;294(5838):268–271.
- Hinuma Y, Nagata K, Hanaoka M, *et al.*: Adult T-cell leukemia: Antigen in an ATL cell line and detection of antibodies to the antigen in human sera. *Proc Natl Acad Sci USA* 1981;78(10):6476–6480.
- Osame M, Usuku K, Izumo S, *et al.*: HTLV-I associated myelopathy, a new clinical entity. *Lancet* 1986;1(8488): 1031–1032.


4. Jacobson S, Raine CS, Mingioli ES, and McFarlin DE: Isolation of an HTLV-1-like retrovirus from patients with tropical spastic paraparesis. *Nature* 1988;331(6156):540–543.
5. Proietti FA, Carneiro-Proietti AB, Catalan-Soares BC, and Murphy EL: Global epidemiology of HTLV-I infection and associated diseases. *Oncogene* 2005;24(39):6058–6068.
6. Igakura T, Stinchcombe JC, Goon PK, *et al.*: Spread of HTLV-I between lymphocytes by virus-induced polarization of the cytoskeleton. *Science* 2003;299(5613):1713–1716.
7. Pais-Correia AM, Sachse M, Guadagnini S, *et al.*: Biofilm-like extracellular viral assemblies mediate HTLV-1 cell-to-cell transmission at virological synapses. *Nat Med* 2010;16(1):83–89.
8. Kinoshita T, Shimoyama M, Tobinai K, *et al.*: Detection of mRNA for the *tax1/rex1* gene of human T-cell leukemia virus type I in fresh peripheral blood mononuclear cells of adult T-cell leukemia patients and viral carriers by using the polymerase chain reaction. *Proc Natl Acad Sci USA* 1989;86(14):5620–5624.
9. Hinuma Y, Gotoh Y, Sugamura K, *et al.*: A retrovirus associated with human adult T-cell leukemia: In vitro activation. *Gann* 1982;73(2):341–344.
10. Hanon E, Hall S, Taylor GP, *et al.*: Abundant tax protein expression in CD4+ T cells infected with human T-cell lymphotropic virus type I (HTLV-I) is prevented by cytotoxic T lymphocytes. *Blood* 2000;95(4):1386–1392.
11. Gotoh YI, Sugamura K, and Hinuma Y: Healthy carriers of a human retrovirus, adult T-cell leukemia virus (ATLV): Demonstration by clonal culture of ATLV-carrying T cells from peripheral blood. *Proc Natl Acad Sci USA* 1982;79(15):4780–4782.
12. Bai XT and Nicot C: Overview on HTLV-1 p12, p8, p30, p13: Accomplices in persistent infection and viral pathogenesis. *Front Microbiol* 2012;3:400.
13. Bangham CR and Osame M: Cellular immune response to HTLV-1. *Oncogene* 2005;24(39):6035–6046.
14. Goncalves DU, Proietti FA, Ribas JG, *et al.*: Epidemiology, treatment, and prevention of human T-cell leukemia virus type I-associated diseases. *Clin Microbiol Rev* 2010;23(3):577–589.
15. Gessain A, Gallo RC, and Franchini G: Low degree of human T-cell leukemia/lymphoma virus type I genetic drift in vivo as a means of monitoring viral transmission and movement of ancient human populations. *J Virol* 1992;66(4):2288–2295.
16. Bonsignori M, Pollara J, Moody MA, *et al.*: Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VHI gene family. *J Virol* 2012;86(21):11521–11532.
17. Miyakoshi H, Koide H, and Aoki T: In vitro antibody-dependent cellular cytotoxicity against human T-cell leukemia/lymphoma virus (HTLV)-producing cells. *Int J Cancer* 1984;33(3):287–291.
18. Sinclair AL, Habeshaw JA, Muir L, *et al.*: Antibody-dependent cell-mediated cytotoxicity: Comparison between HTLV-I and HIV-1 assays. *AIDS* 1988;2(6):465–472.
19. Kozuru M, Uike N, Takeichi N, *et al.*: The possible mode of escape of adult T-cell leukaemia cells from antibody-dependent cellular cytotoxicity. *Br J Haematol* 1989;72(4):502–506.
20. Uno H, Kawano K, Matsuoka H, and Tsuda K: Natural killer activity and antibody-dependent cellular cytotoxicity in patients with adult T-cell leukemia. *Nihon Ketsueki Gakkai Zasshi* 1989;52(4):730–739.
21. Kunitomi T, Takigawa H, Sugita M, *et al.*: Antibody-dependent cellular cytotoxicity and natural killer activity against HTLV-1 infected cells. *Acta Paediatr Jpn* 1990;32(1):16–19.
22. Kuroki M, Nakamura M, Itoyama Y, *et al.*: Identification of new epitopes recognized by human monoclonal antibodies with neutralizing and antibody-dependent cellular cytotoxicity activities specific for human T cell leukemia virus type I. *J Immunol* 1992;149(3):940–948.
23. Zhang XQ, Yang L, Ho DD, *et al.*: Human T lymphotropic virus types I- and II-specific antibody-dependent cellular cytotoxicity: Strain specificity and epitope mapping. *J Infect Dis* 1992;165(5):805–812.
24. Kuo CW, Mirsaliotis A, and Brighty DW: Antibodies to the envelope glycoprotein of human T cell leukemia virus type I robustly activate cell-mediated cytotoxic responses and directly neutralize viral infectivity at multiple steps of the entry process. *J Immunol* 2011;187(1):361–371.
25. Schneider J, Yamamoto N, Hinuma Y, and Hunsmann G: Sera from adult T-cell leukemia patients react with envelope and core polypeptides of adult T-cell leukemia virus. *Virology* 1984;132(1):1–11.
26. Lal RB: Delineation of immunodominant epitopes of human T-lymphotropic virus types I and II and their usefulness in developing serologic assays for detection of antibodies to HTLV-I and HTLV-II. *J Acquir Immune Defic Syndr Hum Retrovirol* 1996;13(Suppl 1):S170–178.
27. Horal P, Hall WW, Svennerholm B, *et al.*: Identification of type-specific linear epitopes in the glycoproteins gp46 and gp21 of human T-cell leukemia viruses type I and type II using synthetic peptides. *Proc Natl Acad Sci USA* 1991;88(13):5754–5758.
28. Tochikura T, Iwahashi M, Matsumoto T, Koyanagi Y, Hinuma Y, and Yamamoto N: Effect of human serum anti-HTLV antibodies on viral antigen induction in vitro cultured peripheral lymphocytes from adult T-cell leukemia patients and healthy virus carriers. *Int J Cancer* 1985;36(1):1–7.
29. Tanaka Y, Zeng L, Shiraki H, Shida H, and Tozawa H: Identification of a neutralization epitope on the envelope gp46 antigen of human T cell leukemia virus type I and induction of neutralizing antibody by peptide immunization. *J Immunol* 1991;147(1):354–360.
30. Tanaka Y, Inoi T, Tozawa H, Yamamoto N, and Hinuma Y: A glycoprotein antigen detected with new monoclonal antibodies on the surface of human lymphocytes infected with human T-cell leukemia virus type-I (HTLV-I). *Int J Cancer* 1985;36(5):549–555.
31. Tanaka Y, Lee B, Inoi T, Tozawa H, Yamamoto N, and Hinuma Y: Antigens related to three core proteins of HTLV-I (p24, p19 and p15) and their intracellular localizations, as defined by monoclonal antibodies. *Int J Cancer* 1986;37(1):35–42.
32. Tanaka Y, Yasumoto M, Nyunoya H, *et al.*: Generation and characterization of monoclonal antibodies against multiple epitopes on the C-terminal half of envelope gp46 of human T-cell leukemia virus type-I (HTLV-I). *Int J Cancer* 1990;46(4):675–681.
33. Inudoh M, Kato N, and Tanaka Y: New monoclonal antibodies against a recombinant second envelope protein of hepatitis C virus. *Microbiol Immunol* 1998;42(12):875–877.

34. Tanaka R, Takahashi Y, Kodama A, Saito M, Ansari AA, and Tanaka Y: Suppression of CCR5-tropic HIV type 1 infection by OX40 stimulation via enhanced production of beta-chemokines. *AIDS Res Hum Retroviruses* 2010; 26(10):1147–1154.
35. Gillis S and Watson J: Biochemical and biological characterization of lymphocyte regulatory molecules. V. Identification of an interleukin 2-producing human leukemia T cell line. *J Exp Med* 1980;152(6):1709–1719.
36. Baba E, Nakamura M, Ohkuma K, *et al.*: A peptide-based human T cell leukemia virus type I vaccine containing T and B cell epitopes that induces high titers of neutralizing antibodies. *J Immunol* 1995;154(1):399–412.
37. Tanaka Y, Tozawa H, Koyanagi Y, and Shida H: Recognition of human T cell leukemia virus type I (HTLV-I) gag and pX gene products by MHC-restricted cytotoxic T lymphocytes induced in rats against syngeneic HTLV-I-infected cells. *J Immunol* 1990;144(11):4202–4211.
38. Melamed A, Laydon DJ, Gillet NA, Tanaka Y, Taylor GP, and Bangham CR: Genome-wide determinants of proviral targeting, clonal abundance and expression in natural HTLV-1 infection. *PLoS Pathog* 2013;9(3):e1003271.
39. Taniguchi Y, Nosaka K, Yasunaga J, *et al.*: Silencing of human T-cell leukemia virus type I gene transcription by epigenetic mechanisms. *Retrovirology* 2005;2:64.
40. Fujihara K, Itoyama Y, Yu F, Kubo C, and Goto I: Antibody-dependent cell-mediated cytotoxicity (ADCC) in HTLV-I associated myelopathy/tropical spastic paraparesis (HAM/TSP). *J Neurol Sci* 1996;142(1–2):65–69.
41. Song ES, Young K, and Sears DW: Rat and human natural killers exhibit contrasting immunoglobulin G subclass specificities in antibody-dependent cellular cytotoxicity reflecting differences in their Fc receptors (Fc gamma R). *J Leukoc Biol* 1990;48(6):524–530.
42. Ackerman ME, Crispin M, Yu X, *et al.*: Natural variation in Fc glycosylation of HIV-specific antibodies impacts antiviral activity. *J Clin Invest* 2013;123(5):2183–2192.
43. Lo KM, Vivier E, Rochet N, *et al.*: Infection of human natural killer (NK) cells with replication-defective human T cell leukemia virus type I provirus. Increased proliferative capacity and prolonged survival of functionally competent NK cells. *J Immunol* 1992;149(12):4101–4108.
44. Wesch D, Marx S, and Kabelitz D: Monocyte-dependent death of freshly isolated T lymphocytes: Induction by phorbol ester and mitogens and differential effects of catalase. *J Immunol* 1998;161(3):1248–1256.

Address correspondence to:

Yuetsu Tanaka
Department of Immunology
Graduate School of Medicine
University of the Ryukyus
207 Uehara, Nishihara-cho
Okinawa 903-0215
Japan

E-mail: yuetsu@s4.dion.ne.jp



HTLV-1 infects human mesenchymal stromal cell *in vitro* and modifies their phenotypic characteristics[☆]



Evandra Strazza Rodrigues^{a,b}, Mayra Dorigan de Macedo^{a,b}, Mariana Tomazini Pinto^{a,b}, Maristela Delgado Orellana^{a,c}, Maurício Cristiano Rocha Junior^{a,b}, Danielle Aparecida Rosa de Magalhães^a, Yuetsu Tanaka^d, Osvaldo Massaiti Takayanagui^c, Dimas Tadeu Covas^{a,c}, Simone Kashima^{a,b,*}

^a Regional Blood Center of Ribeirão Preto, University of São Paulo, Brazil

^b School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Brazil

^c School of Medicine of Ribeirão Preto, University of São Paulo, Brazil

^d University of the Ryukyus, Okinawa, Japan

ARTICLE INFO

Article history:

Received 23 July 2013

Returned to author for revisions

13 September 2013

Accepted 13 November 2013

Available online 6 December 2013

Keywords:

HTLV-1

Human mesenchymal stromal cells

MSC differentiation

MSC virus infection

ABSTRACT

The typical characteristics of mesenchymal stem cells (MSCs) can be affected by inflammatory microenvironment; however, the exact contribution of HTLV-1 to MSC dysfunction remains to be elucidated. In this study, we demonstrated that MSC cell surface molecules VCAM-1 and ICAM-1 are upregulated by contact with HTLV-1, and HLA-DR was most highly expressed in MSCs co-cultured with MT2 cells. The expression levels of VCAM-1 and HLA-DR were increased in MSCs cultured in the presence of PBMCs isolated from HTLV-1-infected symptomatic individuals compared with those cultured with cells from asymptomatic infected individuals or healthy subjects. HTLV-1 does not impair the MSC differentiation process into osteocytes and adipocytes. In addition, MSCs were efficiently infected with HTLV-1 *in vitro* through direct contact with HTLV-1-infected cells; however, cell-free virus particles were not capable of causing infection. In summary, HTLV-1 can alter MSC function, and this mechanism may contribute to the pathogenesis of this viral infection.

© 2013 Published by Elsevier Inc.

Background

Human T lymphotropic virus type 1 (HTLV-1) is a human retrovirus that is associated with two major diseases known as

Abbreviations: MSC, mesenchymal stromal cells; BM, bone marrow; PBMC, peripheral blood mononuclear cells; HAM/TSP, HTLV-associated myelopathy/tropical spastic paraparesis; HAC, HTLV asymptomatic carriers; ATLL, adult T-cell leukemia/lymphoma; CMV, cytomegalovirus; HHV, human herpesvirus, HHV8; PPAR γ , peroxisome proliferator-activated receptors gamma; RUNX-2, runt-related transcription factor-2; CD73, NT5E, 5-nucleotidase, ecto; HLA-class I, human major histocompatibility complex, class I; CD45, leukocyte common; CD90, THY1, Thy-1 cell surface antigen; CD105, ENG, endoglin; CD106, VCAM1, vascular cell adhesion molecule 1; CD13, aminopeptidase-N; HLA-ABC, human major histocompatibility complex (MHC) class I, HLA-A, B, C; CD271, NGFR, nerve growth factor receptor; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; ACTB, beta-actin; NRP1, neuropilins 1; HSPG2, heparan sulfate proteoglycan 2; GLUT1, solute carrier family 2 (facilitated glucose transporter), member 1; URE, expression relative units

[☆]Institution where processing and analysis were performed: Molecular Biology Laboratory, Regional Blood Center of Ribeirão Preto, Rua Tenente Catão Roxo 2501, 14051-140 Ribeirão Preto, São Paulo, Brazil.

* Corresponding author at: Regional Blood Center of Ribeirão Preto, Avenida Tenente Catão Roxo 2501, Ribeirão Preto, São Paulo, Brazil. Fax: +55 16 2101 9309.

E-mail address: skashima@hemocentro.fmrp.usp.br (S. Kashima).

adult T-cell leukemia/lymphoma (ATLL) and HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). Only a small fraction (0.25% to 5%) of HTLV-1-infected individuals develops HAM/TSP, whereas 2% to 5% develop ATLL (Osame et al., 1986; Uchiyama, 1997), but other inflammatory disorders, including myositis, peripheral neuropathy, uveitis, arthritis, Sjögren syndrome, and alveolitis, have also been related to HTLV-1 infection (Oh and Jacobson, 2008). HAM/TSP is characterized as a chronic progressive inflammatory disease that initiates as an inflammatory disorder and progresses to a chronic long-term degenerative disease (Araújo et al., 1995). This inflammatory response can be characterized by the presence of HTLV-1-specific antibodies and the infiltration of T lymphocytes into the peripheral blood and cerebrospinal fluid (CSF). In response to the presence of HTLV-1, CNS infiltrating lymphocytes and resident cell populations trigger the release of cytotoxins, particularly pro-inflammatory cytokines, such as tumor necrosis factor- α (TNF- α) and interferon- γ (IFN- γ), to cause an inflammatory response (Umehara et al., 1993, 1994; Jacobson et al., 1992).

It is still unclear why only a small subset of HTLV-1-infected individuals develops clinical diseases whereas the majority remains HTLV-1 asymptomatic carriers (HACs). Previous studies